Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$102.96 USD

102.96
5,272,970

+0.01 (0.01%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $102.92 -0.04 (-0.04%) 7:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Radhika Pujara headshot

Skyworks (SWKS) & 3 Other Suppliers to Tap Uptick in iPhone Sales

by Radhika Pujara

Shares of Skyworks (SWKS) are skyrocketing post upbeat guidance and impressive Q1 performance driven by uptick in Apple's (AAPL) iPhone 12 sales. This positions other suppliers, including QRVO, JBL & SYNA, well to gain from the projected increase in iPhone 12 demand.

Zacks Equity Research

Skyworks' (SWKS) Q1 Earnings Top Estimates, Stock Up on Q2 View

by Zacks Equity Research

Skyworks' (SWKS) fiscal first-quarter results gain from rapid 5G deployment and strength in overall broad markets.

Zacks Equity Research

Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings

by Zacks Equity Research

Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.

Zacks Equity Research

Boston Scientific's (BSX) DBS System Gets FDA's Clearance

by Zacks Equity Research

The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.

Zacks Equity Research

Boston Scientific (BSX) Enhances Core Business With Buyout

by Zacks Equity Research

Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.

Sriparna Ghosal headshot

3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021

by Sriparna Ghosal

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.

Zacks Equity Research

Boston Scientific's (BSX) SCS Systems Receives FDA's Nod

by Zacks Equity Research

Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.

Zacks Equity Research

Why Is Boston Scientific (BSX) Down 1.5% Since Last Earnings Report?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Medical Products Industry

by Trina Mukherjee

Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.

Zacks Equity Research

Boston Scientific (BSX) in Focus: Stock Moves 7% Higher

by Zacks Equity Research

Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Boston Scientific (BSX) Q3 Earnings Top, Margins Decline

by Zacks Equity Research

Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.

Zacks Equity Research

Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 48.00% and 5.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Q3 Earnings on Oct 28: BSX, CERN & More

by Urmimala Biswas

In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.

Zacks Equity Research

Boston Scientific (BSX) Q3 Earnings to Grow on Vital Procedures

by Zacks Equity Research

Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.

Zacks Equity Research

Analysts Estimate Boston Scientific (BSX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Align's (ALGN) ClinCheck Suite Now Commercially Available

by Zacks Equity Research

Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.

Zacks Equity Research

Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View

by Zacks Equity Research

Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.

Zacks Equity Research

Baxter Supports Findings of Ongoing COVID-19 Nutrition Study

by Zacks Equity Research

The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Zacks Equity Research

LHC Group (LHCG) and CHRISTUS Health Extend JV Partnership

by Zacks Equity Research

LHC Group (LHCG) and CHRISTUS Health expand their partnership to boost home health services and hospice care.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.

Zacks Equity Research

Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

by Zacks Equity Research

AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

Zacks Equity Research

Allscripts Completes Sale of EPSi Business to Strata

by Zacks Equity Research

Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health